In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Roivant Sciences (ROIV – Research Report). The company’s ...

Roivant Sciences Ltd. (NASDAQ:ROIV), a pharmaceutical company with a market capitalization of $7.8 billion and a "GOOD" financial health rating according to InvestingPro, disclosed on Thursday ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.

Vivek Ramaswamy’s Roivant group has forged its biggest and most wide-ranging alliance to date, licensing dozens of drugs to Japan’s Sumitomo Dainippon Pharma in deal that includes a massive $3 ...

Viking Global's 13F stock portfolio increased from $27.44B to $30.90B, with holdings rising from 83 to 86. Read more to see ...

Pharmaceutical companies had more patents ... while other potential medicines would languish. In 2014, he founded Roivant Sciences to buy or license promising drugs that weren’t a priority ...

In Roivant, Pfizer has a partner with "a proven track record in late-stage inflammation and immunology drug development," said the big pharma's chief scientific officer Mikael Dolsten. Hiving off ...

Ramaswamy worked as an investment partner at a hedge fund before founding Roivant Sciences, a pharmaceutical company, in 2014. He also co-founded an investment firm, Strive Asset Management.

It’s the latest development in a bitter patent feud in which Arbutus and Genevant, a joint venture between Arbutus and Roivant that holds ... respond to Fierce Pharma’s request for comment.